203 related articles for article (PubMed ID: 36990046)
41. Landscape of Acquired Resistance to Osimertinib in
Piotrowska Z; Isozaki H; Lennerz JK; Gainor JF; Lennes IT; Zhu VW; Marcoux N; Banwait MK; Digumarthy SR; Su W; Yoda S; Riley AK; Nangia V; Lin JJ; Nagy RJ; Lanman RB; Dias-Santagata D; Mino-Kenudson M; Iafrate AJ; Heist RS; Shaw AT; Evans EK; Clifford C; Ou SI; Wolf B; Hata AN; Sequist LV
Cancer Discov; 2018 Dec; 8(12):1529-1539. PubMed ID: 30257958
[TBL] [Abstract][Full Text] [Related]
42. Transcriptional targeting of oncogene addiction in medullary thyroid cancer.
Valenciaga A; Saji M; Yu L; Zhang X; Bumrah C; Yilmaz AS; Knippler CM; Miles W; Giordano TJ; Cote GJ; Ringel MD
JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135308
[TBL] [Abstract][Full Text] [Related]
43. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.
Kodama T; Tsukaguchi T; Satoh Y; Yoshida M; Watanabe Y; Kondoh O; Sakamoto H
Mol Cancer Ther; 2014 Dec; 13(12):2910-8. PubMed ID: 25349307
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of RET increases the efficacy of antiestrogen and is a novel treatment strategy for luminal breast cancer.
Spanheimer PM; Park JM; Askeland RW; Kulak MV; Woodfield GW; De Andrade JP; Cyr AR; Sugg SL; Thomas A; Weigel RJ
Clin Cancer Res; 2014 Apr; 20(8):2115-25. PubMed ID: 24526731
[TBL] [Abstract][Full Text] [Related]
45. Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes.
Rocco D; Sapio L; Della Gravara L; Naviglio S; Gridelli C
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768754
[TBL] [Abstract][Full Text] [Related]
46. Design, synthesis, biological activity evaluation of 3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives as potent JAK 2/3 and aurora A/B kinases multi-targeted inhibitors.
Zheng YG; Wang JA; Meng L; Pei X; Zhang L; An L; Li CL; Miao YL
Eur J Med Chem; 2021 Jan; 209():112934. PubMed ID: 33109396
[TBL] [Abstract][Full Text] [Related]
47. Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases.
Sahni JM; Gayle SS; Bonk KL; Vite LC; Yori JL; Webb B; Ramos EK; Seachrist DD; Landis MD; Chang JC; Bradner JE; Keri RA
J Biol Chem; 2016 Nov; 291(45):23756-23768. PubMed ID: 27650498
[TBL] [Abstract][Full Text] [Related]
48. Aurora-A Kinase: A Potent Oncogene and Target for Cancer Therapy.
Yan M; Wang C; He B; Yang M; Tong M; Long Z; Liu B; Peng F; Xu L; Zhang Y; Liang D; Lei H; Subrata S; Kelley KW; Lam EW; Jin B; Liu Q
Med Res Rev; 2016 Nov; 36(6):1036-1079. PubMed ID: 27406026
[TBL] [Abstract][Full Text] [Related]
49. RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer.
Wang C; Zhang Z; Sun Y; Wang S; Wu M; Ou Q; Xu Y; Chen Z; Shao Y; Liu H; Hou P
J Transl Med; 2022 Sep; 20(1):390. PubMed ID: 36059009
[TBL] [Abstract][Full Text] [Related]
50. An early look at selective RET inhibitor resistance: new challenges and opportunities.
Lin JJ; Gainor JF
Br J Cancer; 2021 May; 124(11):1757-1758. PubMed ID: 33758332
[TBL] [Abstract][Full Text] [Related]
51. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
Gainor JF; Curigliano G; Kim DW; Lee DH; Besse B; Baik CS; Doebele RC; Cassier PA; Lopes G; Tan DSW; Garralda E; Paz-Ares LG; Cho BC; Gadgeel SM; Thomas M; Liu SV; Taylor MH; Mansfield AS; Zhu VW; Clifford C; Zhang H; Palmer M; Green J; Turner CD; Subbiah V
Lancet Oncol; 2021 Jul; 22(7):959-969. PubMed ID: 34118197
[TBL] [Abstract][Full Text] [Related]
52. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
53. Loss of Aurora Kinase Signaling Allows Lung Cancer Cells to Adopt Endoreplication and Form Polyploid Giant Cancer Cells That Resist Antimitotic Drugs.
Tagal V; Roth MG
Cancer Res; 2021 Jan; 81(2):400-413. PubMed ID: 33172929
[TBL] [Abstract][Full Text] [Related]
54. RET fusion gene: translation to personalized lung cancer therapy.
Kohno T; Tsuta K; Tsuchihara K; Nakaoku T; Yoh K; Goto K
Cancer Sci; 2013 Nov; 104(11):1396-400. PubMed ID: 23991695
[TBL] [Abstract][Full Text] [Related]
55. Selective RET kinase inhibition for patients with RET-altered cancers.
Subbiah V; Velcheti V; Tuch BB; Ebata K; Busaidy NL; Cabanillas ME; Wirth LJ; Stock S; Smith S; Lauriault V; Corsi-Travali S; Henry D; Burkard M; Hamor R; Bouhana K; Winski S; Wallace RD; Hartley D; Rhodes S; Reddy M; Brandhuber BJ; Andrews S; Rothenberg SM; Drilon A
Ann Oncol; 2018 Aug; 29(8):1869-1876. PubMed ID: 29912274
[TBL] [Abstract][Full Text] [Related]
56. Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling.
Nelson-Taylor SK; Le AT; Yoo M; Schubert L; Mishall KM; Doak A; Varella-Garcia M; Tan AC; Doebele RC
Mol Cancer Ther; 2017 Aug; 16(8):1623-1633. PubMed ID: 28500237
[TBL] [Abstract][Full Text] [Related]
57. Discovery of 3,5-diaryl-1H-pyrazol-based ureas as potent RET inhibitors.
Wu K; He R; Li Z; Qiu K; Xiao G; Peng L; Meng X; Zheng C; Zhang Z; Cai Q
Eur J Med Chem; 2023 May; 251():115237. PubMed ID: 36905915
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cells.
Illert AL; Seitz AK; Rummelt C; Kreutmair S; Engh RA; Goodstal S; Peschel C; Duyster J; von Bubnoff N
PLoS One; 2014; 9(11):e112318. PubMed ID: 25426931
[TBL] [Abstract][Full Text] [Related]
59. TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways.
Miura A; Sootome H; Fujita N; Suzuki T; Fukushima H; Mizuarai S; Masuko N; Ito K; Hashimoto A; Uto Y; Sugimoto T; Takahashi H; Mitsuya M; Hirai H
Invest New Drugs; 2021 Jun; 39(3):724-735. PubMed ID: 33409897
[TBL] [Abstract][Full Text] [Related]
60. The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies.
Hicks HM; Nassar VL; Lund J; Rose MM; Schweppe RE
Cancer Biol Ther; 2024 Dec; 25(1):2332000. PubMed ID: 38521968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]